Diagnostic 131I whole body scanning after thyroidectomy and ablation for differentiated thyroid cancer.

Objective : To assess the value of the diagnostic whole body 131 I scan after thyroidectomy and 131 I ablation. Design : Retrospective analysis of all patients with differentiated thyroid cancer treated in one centre between 1990 and 2000. Results : A total of 153 consecutive patients who underwent diagnostic scanning following ablative therapy were identified. This diagnostic scan was positive in 20 patients (13%) and faintly positive in 16 patients (11%). The majority (117 patients) had negative scans. Of the 20 patients with positive scans, four received no further treatment, nine showed no abnormal uptake following a second ablative 131 I dose and seven had uptake in the thyroid bed (six) or in neck nodes (one) after repeat ablation. Outcome : In the group with positive scans, the four patients who received no further treatment and the nine with a negative second ablation scan remained disease free during follow-up. No patient with a positive diagnostic scan received additional 131 I therapy which would not otherwise have been given based on the clinical findings, serum thyroglobulin (Tg) values or the presence of anti-Tg antibodies. Ten of the patients with negative scans developed recurrent disease which was always detected clinically or by a rising serum Tg value. Conclusions : Diagnostic whole body 131 I scans add little extra information and in our experience do not influence patient management. They should be reserved for patients in whom serum Tg levels are unreliable because of the presence of antibodies or when there is clinical suspicion of tumour. European Journal of Endocrinology 150 649–653

[1]  W. Lees,et al.  The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  R. Kloos,et al.  Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? , 2002, The Journal of clinical endocrinology and metabolism.

[3]  A. Pinchera,et al.  Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. , 2002, The Journal of clinical endocrinology and metabolism.

[4]  C. Harmer,et al.  Radioiodine treatment for differentiated thyroid cancer. , 2000, Clinical oncology (Royal College of Radiologists (Great Britain)).

[5]  M. Schlumberger,et al.  Clinical use of recombinant human TSH in thyroid cancer patients. , 2000, European journal of endocrinology.

[6]  C. Fisher,et al.  Recurrent differentiated thyroid cancer without elevation of serum thyroglobulin. , 2000, Thyroid : official journal of the American Thyroid Association.

[7]  J. Nicoloff,et al.  Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. , 1999, Thyroid : official journal of the American Thyroid Association.

[8]  P. Grigsby,et al.  Surveillance of patients to detect recurrent thyroid carcinoma , 1999, Cancer.

[9]  E. Baudin,et al.  Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. , 1998, European journal of endocrinology.

[10]  J. Reynolds Percent 131I uptake and post-therapy 131I scans: their role in the management of thyroid cancer. , 1997, Thyroid : official journal of the American Thyroid Association.

[11]  A. Pinchera,et al.  Assay of thyroglobulin in serum with thyroglobulin autoantibodies: an unobtainable goal? , 1995, The Journal of clinical endocrinology and metabolism.

[12]  D. Johnston,et al.  The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. , 1992, The Journal of clinical endocrinology and metabolism.

[13]  A. Di Giorgio,et al.  Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer. , 2003, European journal of endocrinology.

[14]  P. Lind Should high hTg levels in the absence of iodine uptake be treated? , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  E. Baudin,et al.  Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? , 2000, The Journal of clinical endocrinology and metabolism.